Alveo Technologies Successfully Fulfills Expanded CDC Milestone Agreement to Advance its Rapid Molecular Test for both Seasonal and Avian Influenza A(H5) in Humans

Using both nasal and conjunctival sample types, Alveo's point of care, cloud-connected molecular testing solution detects and differentiates between Influenzas A, B and A(H5) in humans ALAMEDA, Calif., Aug. 26, 2025 /PRNewswire/ -- Alveo Technologies, Inc. (Alveo), a leader in molecular...